secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001213900-23-086486
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences Q3 2023 net income $0.1M vs loss of $0.4M year ago
-----------------------------------------------------------------------

- Q3 net revenues $5.0M, up from $4.9M in Q3 2022; nine-month revenues $22.5M vs $12.5M.
- Q3 income from operations $0.02M, compared to operating loss of $0.7M in Q3 2022.
- Net loss for nine months 2023 was $4.9M ($0.09/share), improved from $10.8M ($0.22/share) in 2022.
- Inventory shortage of Endari caused lower Q3 sales; remedied, expects recovery in Q4.
- Cash and cash equivalents $1.5M at Sep 30, 2023, down from $2.0M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/0001213900-23-086486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390023086486/ea188263-8k_emmaus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-086486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer